Cytosin-Arabinosid
Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
University of California, DavisPhase 2Active
B
58/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 81/ 100
Competitive context
23 Active assets in the Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Roswell Park Cancer Institute | Phase 2 | B |
Axicabtagene Ciloleucel City of Hope Medical Center | Phase 2 | B |
Fludarabine Roswell Park Cancer Institute | Phase 2 | B |
ETOPOSIDE University of California, Davis | Phase 2 | B |
cc-5013 David Bond, MD | Phase 2 | B |
View all 26 →
Same molecule, other indications
Cytosin-Arabinosid is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →